Personalized medicine: risk prediction, targeted therapies and mobile health technology

Personalized medicine is increasingly being employed across many areas of clinical practice, as genes associated with specific diseases are discovered and targeted therapies are developed. Mobile apps are also beginning to be used in medicine with the aim of providing a personalized approach to disease management. In some areas of medicine, patient-tailored risk prediction and treatment are applied routinely in the clinic, whereas in other fields, more work is required to translate scientific advances into individualized treatment. In this forum article, we asked specialists in oncology, neurology, endocrinology and mobile health technology to discuss where we are in terms of personalized medicine, and address their visions for the future and the challenges that remain in their respective fields.

[1]  A. Tahrani,et al.  Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? , 2007, BMJ : British Medical Journal.

[2]  D. Matthews,et al.  N of 1 trials in diabetes: making individual therapeutic decisions , 2008, Diabetologia.

[3]  B. Howard,et al.  Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials , 2009, Diabetes Care.

[4]  J. Bozell.  Breaking the vicious cycle. , 2007, Mental health today.

[5]  Jung A Kim.  The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care , 2011 .

[6]  Mark Woodward,et al.  Severe hypoglycemia and risks of vascular events and death. , 2010, The New England journal of medicine.

[7]  A. Tenenbaum,et al.  Cardiovascular Diabetology BioMed Central Review , 2008 .

[8]  J. Herman,et al.  Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Craig I Coleman,et al.  Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. , 2010, JAMA.

[10]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[11]  Paolo Pozzilli,et al.  The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach , 2010, Diabetes/metabolism research and reviews.

[12]  Hugh S Markus,et al.  Stroke genetics: prospects for personalized medicine , 2012, BMC Medicine.

[13]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[14]  A. de Leiva,et al.  Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype , 2013, Diabetes Care.

[15]  Lisa M McShane,et al.  Publication of tumor marker research results: the necessity for complete and transparent reporting. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[17]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[18]  G. Omenn,et al.  Evolution of Translational Omics: Lessons Learned and the Path Forward , 2013 .